产品描述信息
NR-18853??Mycobacterium tuberculosis, CDC1551, Transposon Mutant 3170 (MT2762, Rv2688c)(Mutant Bacteria)|Mycobacterium tuberculosis|CDC1551, Transposon Mutant 3170 (MT2762, Rv2688c)|2°C to 8°C|NIH - TB Vaccine Testing and Research Materials ContractAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain CDC1551, Transposon Mutant 3170 (MT2762, Rv2688c), NR-18853."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. At this time, BEI Resources only maintains seed stock of this item. Once a request is received for this item, it will be added to our production queue. Please allow ample time for distribution lots to be made available. In 2002,
TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of Mycobacterium tuberculosis (M. tuberculosis). In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized. M. tuberculosis, transposon mutant 3170 was created by disruption of a probable ABC transporter, ATP-binding protein (MT2762, Rv2688c) of the wild-type strain CDC1551.Each tube contains a Lowenstein-Jensen (LJ) agar slant that was inoculated with 0.1 mL of bacterial culture and incubated 2 to 6 weeks at 37°C.TARGET:
Rv2688cMT Number (JCVI):
MT2762TubercuList:
Rv2688cORF Description: Probable ABC transporter, ATP-binding proteinORF Size: 954POI: 476Additional information is available at
Mycobacterium tuberculosis CDC1551 Transposon Mutant Library.This mutant was developed by Lamichhane, et al. at the Center for Tuberculosis Research, The Johns Hopkins University School of Medicine, PubMed:
12775759.